Professor Dale Bailey brings link to Translational Cancer Centre
Sydney, Australia, 18 Dec 2014 – Sydney based biotech company Clarity Pharmaceuticals is pleased to announce that Professor Dale Bailey from PharmaScint, a specialist clinical trials imaging and analysis organization, has joined their expert scientific advisory group. In addition to being a Director of PharmScint, Professor Bailey is Principal Physicist in the Department of Nuclear Medicine at Sydney’s Royal North Shore Hospital and Professor in Medical Radiation Sciences at the University of Sydney. He also leads the Neuro-Endocrine Tumour flagship of Sydney Vital – the Northern Translational Cancer Research Centre.
Professor Bailey said that it is exciting to join a new breed of innovative Australian startup that has proven expertise in attracting investment for commercialisation and the skill set to develop radiopharmaceutical product pipelines.
“My focus will be on advising the best approach to take the products from the lab to the clinic and matching the right imaging with the pipeline products” he said.
Executive Chairman of Clarity Pharmaceuticals, Dr Alan Taylor said that “it is timely to have an esteemed nuclear medicine physicist join our rapidly growing company as we prepare to move into early stage clinical trials with our radiopharmaceutical pipeline”.
“Professor Bailey brings strong clinical experience and a potential collaboration with the nearby Royal North Shore Hospital with a path to progress our radiopharmaceutical pipeline into the clinic”.
About PharmaScint
PharmaScint (www.pharmascint.com) is a medical imaging service organisation that provides clinical imaging trial, data management, and analysis solutions to the pharmaceutical industry. The focus on this niche market is to aid clients in evaluating optimal delivery routes and optimisation for new pharmaceuticals.
PharmaScint’s intent is to:
• Work predominantly in 3D SPECT and PET imaging and investigate structure/function relations using CT and MRI imaging;
• Develop standardised methodologies and analyses for multi-centric trials;
• Further develop the concept of ‘dose modelling’ by advanced data acquisition and analysis strategies to accelerate the evaluation of new radiopharmaceutricals;
• Capitalise on access to patients with a wide spectrum of conditions to provide more clinically relevant studies for clients.
Prof Dale Bailey Biography
Prof Bailey is Principal Physicist in the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, and Professor in Medical Radiation Sciences at the University of Sydney. He is Co-Director of PharmaScint, a biotech company providing imaging and analytical services to the pharmaceutical industry. Prof Bailey is also the flagship leader for the Neuro-Endocrine tumour (NET) project of Sydney Vital – the Northern Translational Cancer Research Centre. His main area of interest is in the development of quantitative techniques using imaging of in vivo radionuclide tracers in both SPECT (single photon emission computed tomography) and PET (positron emission tomography). Prof Bailey is currently a chief investigator for a number of grants including studying the micro-vascular changes in pulmonary arterial hypertension using ventilation and perfusion SPECT and improving imaging and dosimetry techniques in selective internal radionuclide therapy (SIRT) in liver cancer utilising SIR-Spheres, SPECT and PET.
